ClinVar Miner

Submissions for variant NM_003098.3(SNTA1):c.556G>A (p.Gly186Ser)

gnomAD frequency: 0.00004  dbSNP: rs200755101
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 4
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
GeneDx RCV000171118 SCV000223683 uncertain significance not provided 2016-11-17 criteria provided, single submitter clinical testing The Gly186Ser variant in the SNTA1 gene has not been reported previously as a disease-causing mutation nor as a benign polymorphism, to our knowledge. Gly186Ser results in a non-conservative amino acid substitution of a non-polar Glycine with a neutral, polar Serine at a residue that is conserved across mammal species. The Gly186Ser variant was not detected in up to 600 alleles from control individuals of Caucasian and African American ancestry tested at GeneDx, indicating it is not a common benign variant in these populations. However, no mutations have been reported in this region of the SNTA1 gene to date. In summary, with the clinical and molecular information available at this time, we cannot unequivocally determine whether the Gly186Ser variant is a disease-causing mutation or a rare benign variant. The pathogenic role of this variant would be supported if it arose de novo in an individual or co-segregates with an LQTS phenotype in a family. The variant is found in LQT panel(s).
Invitae RCV000631640 SCV000752723 uncertain significance Long QT syndrome 2023-09-06 criteria provided, single submitter clinical testing This sequence change replaces glycine, which is neutral and non-polar, with serine, which is neutral and polar, at codon 186 of the SNTA1 protein (p.Gly186Ser). This variant is present in population databases (rs200755101, gnomAD 0.005%). This variant has not been reported in the literature in individuals affected with SNTA1-related conditions. ClinVar contains an entry for this variant (Variation ID: 190935). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt SNTA1 protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.
Ambry Genetics RCV002345577 SCV002650908 uncertain significance Cardiovascular phenotype 2023-01-17 criteria provided, single submitter clinical testing The c.556G>A (p.G186S) alteration is located in exon 3 (coding exon 3) of the SNTA1 gene. This alteration results from a G to A substitution at nucleotide position 556, causing the glycine (G) at amino acid position 186 to be replaced by a serine (S). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear.
Fulgent Genetics, Fulgent Genetics RCV002485083 SCV002792727 uncertain significance Long QT syndrome 12 2022-02-15 criteria provided, single submitter clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.